



CEBT
Benefit by Trust

Prescription Benefit Review

July 2023- May 2024

July 15th, 2024

**CVS**Health[®]

Today—Your prescription benefit review

Client Goals

Based on our discussions, as your account team, we are working together toward the following goals:

- Effectively Manage Cost/Trend**
- Provide an Enhanced Member Experience**
- Collaborative Strategic Planning**

In this rapidly evolving landscape, we know that continuous monitoring of the health care market - including trend drivers - and the ability to adapt quickly is essential to help ensure the success of your benefit strategy. Our consultative services play a major role in support of your strategic objectives for managing pharmacy and total health care trend. The insights and recommendations provided within this report will help ensure you have the most relevant and timely information to effectively manage costs and maintain high client/employee satisfaction. We look forward to a meaningful discussion today. Thank you for your time.

Sincerely,

Laney Klar, Strategic Account Executive

Ed Devaney, President, Employer & Health Plans

Richard Edwards, Executive Director

Kurt Neuenfeld, Clinical Advisor

In this RxInsights[®] review we'll:

- Assess how your plan is performing.
- Provide relevant benchmarks to put your numbers in context.
- Discuss how your plan was affected by specific trend drivers.
- Identify anticipated trend drivers.
- Make recommendations that will help reduce trend and achieve plan goals.



Agenda

PBM 101/Marketplace Trends

Clinical Landscape

Utilization & Trend

Program Solutions

PBM 101 & Marketplace Trends

PBMs help clients control costs and improve plan member health outcomes

We are continuously innovating to find new ways of getting the **right medication to the right patient at the right time** – always at the lowest possible cost

Disease management and adherence programs



Pharmacy claims processing



Drug utilization review



Negotiations with drug manufacturers and pharmacies



Specialty pharmacy



Formulary management



Mail service pharmacy



Retail pharmacy network management



Constantly innovating to stay ahead of marketplace trends



Addressing rising drug costs

Drive low net cost by harnessing competition, **focused on biosimilars** and proactive management strategies



- New-to-market review
- Intelligent purchasing
- Formulary strategies
- Provider support
- Utilization management
- Biosimilar strategy



Managing GLP-1s for metabolic health

Comprehensive GLP-1 management that delivers value across the patient journey



- GLP-1 management strategies: coverage, cost and care
- Comprehensive anti-obesity member program
- Diabetes de-prescribing program



Increasing medication affordability

With advanced strategies that help **member affordability**



- Cost Saver™ powered by GoodRx
- PrudentRx solution
- Real-Time Benefits



Meeting changing consumer expectations

By creating a convenient, **digital-forward member experience**



- Digital tools including Symptom Tracker
- Specialty Connect
- Virtual care



Managing key market dynamics and regulation

Creating options that help align clients' cost management and member experience priorities



- Introducing new Choice formularies
- Monitoring regulatory and policy changes that can significantly impact your strategy and costs

Clinical Landscape

Pipeline insights

GLP-1 Pipeline

- Indication expansion including cardiovascular, kidney disease, liver disease
- Applications for disease states beyond diabetes/obesity and associated comorbidities- Alzheimer's disease, mental health
- New mechanisms of action- combination therapy (CargriSema, MariTide, retatrutide)

Innovative treatment options for common chronic conditions

- **Schizophrenia**- KarXT expected Q3 2024 – first in class antipsychotic that's not associated with common side effects of marketed antipsychotics, like weight gain
- **Post Traumatic Stress Disorder**- midomafetamine (MDMA), if approved will be first psychedelic-assisted therapy
- **Pain**- first in class non-opioid drug for moderate-to-severe acute pain

Dynamic Biosimilar Market

- Biosimilars are expected to play critical role in controlling drug spend in the coming years; working with Cordavis to ensure supply quality, reliability and increased competition
- Leveraging RxChange to deliver a frictionless experience for our members and their prescribers transitioning from Humira to a preferred biosimilar



Continued enhancements for GLP-1 management

GLP-1 therapies are a class of medication that controls blood sugar and promotes weight loss by mimicking incretin hormones¹

Continued UM innovation


- ♥ **Antidiabetic GLP-1, GIP-GLP-1 Agonist PA Enhancements** - previous use of incretin mimetics will no longer bypass PA requirement

Additional CVS Caremark Solutions

- Plan Design
- Formulary
- Utilization Management
- Care Management Programs
 - ❖ Transform Diabetes Care

Adding Weight Loss GLP-1 coverage for CEBT:


- **\$3.6M gross cost (annualized)**
- **2,845 Rx's**



Utilization & Trend

Experience Period: July 2023 – May 2024

Demonstrating overall value of PBM management



* Net cost prior to managed program savings, AWP discounts, and rebate impact.

**Any outcomes savings presented for Specialty Guideline Management, Quantity Limits, Prior Authorization, or Step Therapy is for the period Jul-2023 through Apr-2024.


***Any outcomes savings presented for Drug Savings Review is for the period 2023Q3 through 2024Q1.

† Rebates represent client share of invoiced rebates as of report run date of 06-18-2024 and may not reconcile with rebate guarantees or rebates paid to date. Rebates included for this time period: 2023Q3 - 2024Q1.


Key metrics at a glance

Eligibility	Jul-May 23	% Change	Jul-May 24	Jul-May 24	Jul-May 24
Average Eligible Members per Month	32,571	7.1%	34,870	Employer	Peer*
Average Utilizers as % of Members	29.8%	-0.2%	29.7%	34.8%	41.8%
Average Member Age	37	-0.4%	36	36	39
Cost with Rebates**					
Total Gross Cost	\$48,834,034	14.5%	\$55,891,145		
Gross Cost w/ Rebates**	\$36,809,600	3.8%	\$38,207,907		
Total Net Cost w/ Rebates**	\$33,295,383	3.3%	\$34,409,135		
Gross Cost w/ Rebates** PMPM	\$102.74	-3.0%	\$99.61		
Net Cost w/ Rebates** PMPM	\$92.93	-3.5%	\$89.71		
% Total Member Cost Share	7.2%	-5.6%	6.8%	7.9%	7.0%
% Non-Specialty Member Cost Share	14.7%	-4.1%	14.1%	12.2%	11.4%
Drug Mix					
% Single Source Brands	13.4%	-0.1%	13.3%	14.2%	14.4%
% Multi Source Brands	2.4%	-45.3%	1.3%	1.0%	1.0%
Generic Dispensing Rate	84.3%	1.3%	85.4%	84.8%	84.6%
Generic Substitution Rate	97.2%	1.3%	98.5%	98.8%	98.8%
Utilization					
Total Prescriptions	224,458	7.1%	240,329		
% Retail Prescriptions	72.8%	-1.9%	71.4%	79.8%	88.4%
% Mail Prescriptions	4.3%	1.0%	4.4%	20.2%††	11.6%††
Days' Supply PMPM	26.21	2.7%	26.91	35.65	47.28
Specialty					
Specialty Total Gross Cost	\$26,480,736	16.1%	\$30,742,110		
Specialty Avg. Utilizers as % of Members	1.0%	3.2%	1.0%	1.2%	1.4%
Specialty Gross Cost PMPM	\$73.91	8.4%	\$80.15	\$90.24	\$113.66
Specialty % of Total Gross Cost	54.2%	1.4%	55.0%	48.6%	46.9%
Specialty % of Total Prescriptions	1.9%	3.8%	1.9%	1.6%	1.5%
% Specialty Member Cost Share	0.9%	-5.1%	0.8%	3.5%	2.1%

Your gross trend



Your specialty and non-specialty trend



*Peer: Government

** Rebates represent client share of invoiced rebates (less: point of sale rebates) as of report run date of 06-18-2024 and may not reconcile with rebate guarantees or rebates paid to date. Rebates included for this time period: 2023Q3 - 2024Q1. Prior period rebates include the same number of quarters as current period.

††Includes Maintenance Choice® Claims

Your top specialty classes by contribution to trend

Key metrics

Specialty prescriptions represented **55.0%**

of total gross cost and comprised **1.9%** of all prescriptions.

Newly launched medications contributed


0.9%

to specialty trend.

Price inflation contributed

4.9%

to specialty trend.



6.1%

Overall specialty utilization increase compared to prior period



The top three (3) classes with the greatest contribution to specialty drug utilization trend are:
Atopic Dermatitis
Psoriasis
Crohns Disease

Your top 5 contributing specialty classes

Specialty Class	Top Drug Contributors	Gross Cost	Utilizers	Gross Cost PMPM	Contribution to Gross Trend
Psoriasis	Skyrizi, Taltz	\$3,295,753	68	\$8.59 \$13.71	1.9%
Crohns Disease	Stelara, Rinvoq	\$3,325,990	37	\$8.67 \$8.96	1.8%
Atopic Dermatitis	Dupixent, Rinvoq	\$1,493,811	54	\$3.89 \$5.16	1.4%
Multiple Sclerosis	Mavenclad, Kesimpta	\$2,358,051	38	\$6.15 \$5.91	0.9%
Asthma	Dupixent, Nucala	\$1,537,703	60	\$4.01 \$2.97	0.8%

Peer:Government

Your top non-specialty classes by contribution to trend

Key metrics

Non-specialty prescriptions represented

45.0%

of total gross cost and comprised

98.1%


of all prescriptions.

Newly launched medications contributed

1.9%

to non-specialty trend.

■ CEBT
■ Peer



Gross Non-Specialty Trend

2.6%

Overall non-specialty utilization increase compared to prior period



The top three (3) classes with the greatest contribution to non-specialty drug utilization trend are:

- Adhd/Anti-Narcolepsy/Anti-Obesity/Anorexiant
- Antidiabetics
- Antihyperlipidemics

Your top 5 contributing non-specialty classes

Non-Specialty Class	Top Drug Contributors	Gross Cost	Utilizers	Gross Cost PMPM	Contribution to Gross Trend
Antidiabetics	Mounjaro, Ozempic	\$8,390,247	1,929	\$21.87 \$45.64	1.9%
Vaccines	Spikevax Covid-19 Vaccine, Comirnaty 2023-24	\$790,497	4,235	\$2.06 \$3.09	0.6%
Medical Devices And Supplies	Dexcom G7 Sensor, Omnipod 5 G6 Pods (Gen 5)	\$771,317	412	\$2.01 \$2.84	0.6%
Migraine Products	Nurtec, Ubrelvy	\$1,913,719	972	\$4.99 \$6.13	0.5%
Anticoagulants	Eliquis, Fondaparinux Sodium	\$1,206,137	506	\$3.14 \$6.43	0.3%

Peer:Government

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

©2024 CVS Health and/or one of its affiliates: Confidential & Proprietary

Point of Sale Rebates & TrueCost

Point of Sale Rebates: how it works



Pass discounts directly to members at the point of sale*



Estimated at the time of adjudication and applied to help reduce member cost share**



Can be implemented through mail, retail network and specialty pharmacies†



Incorporated in price quote
Check Drug Cost tool on Caremark.com

Rebates paid to clients via standard rebate process

CEBT Traditional Plans: Member cost reduced by \$64,828 at POS, shifts \$0.17 PMPM to plan
CEBT HDHP Plans: Member cost reduced by \$229,267 at POS, shifts \$6.75 PMPM to plan

*Discounts vary based on client formulary, plan design and contracted rates. **POS rebates are estimates based on 100% of client share of rebates collected.

† Not available on out-of-network or paper claims.

TrueCost is reshaping the future of drug pricing and making it clearer and simpler – as it should be



Providing deeper transparency

with drug level, multi-year net cost guarantees across all drugs

Delivering simplicity

with acquisition-cost pricing guarantees to help sustain economic predictability and guide strategic decision-making

Strengthening the value

of your pharmacy benefit, keeping members on benefit when they fill their prescription

Illustrative example

First ever drug level multi-year net cost guarantee

Net cost guarantee example (per unit)

	Net Cost Guarantee ²
Generic drug	\$0.74
Brand drug	\$3.76
Specialty drug	\$2,652.00



Client guarantee inclusive of mark-up and rebates

Actual Pricing Document

GPI14 with B/G	Brand/ Generic	Drug Name, Form and Strength	Year1 Guaranteed Unit Price	Year2 Guaranteed Unit Price	Year3 Guaranteed Unit Price	Rebate Tiers
10203948005000	Generic	DRUG NAME - TAB 20 MG	0.020	0.020	0.019	
10203948003521	Brand	DRUG NAME - CAP 100 MG	1.53	1.59	1.65	1
24090203948002	Brand	DRUG NAME 3- CRM 5MG/ML	4.13	4.29	4.46	3

1. A disclosed drug mark-up *may be applicable* on a client-by-client basis, to ensure appropriate pharmacy network reimbursement based on client's pharmacy utilization
2. Product level pricing will be guaranteed, however, a yearly reconciliation in the aggregate is still required for true-up purposes, inclusive of ingredient costs, dispensing fees, and rebates

PrudentRx

You and your members benefit with the PrudentRx difference



CEBT Net Savings: ~\$3M
Member Savings: ~\$182k

*Based on Jan 2023- Dec 2023 data

More accurate savings

Incremental savings considers previous benefit design in calculating the client net cost

\$0 participating member OOP
for every specialty fill*

Coinsurance set at 30%
across the program drug list**

Seamless member experience,
high-touch member engagement –
integrated effort to help ensure
members are informed and enrolled

Powered by PrudentRx

Independent third-party vendor, 30+combined years experience in health care and specialty.

Expertise in plan design, specialty pharmacy and copay card programs.

Certified minority owned business.

*Participating members enrolled in an HDHP with an HSA must fully satisfy their deductible before they are eligible for a final \$0 OOP cost under the program, unless the member has been prescribed a medication that qualifies as “preventive care” under the IRC, which is administered and enforced by the IRS. Members may still utilize available copay assistance while in their deductible phase but must satisfy their deductible before the Plan is able to pick up any of the costs on the members’ behalf. **Due to limitations that exist within various external pharmacy systems, implementing the PrudentRx solution on HDHPs with HSAs will be limited to only those medications included on the client’s specialty drug list and dispensed by CVS Specialty and will not include limited distribution no access drugs.

**Thank
You**



Appendix

Ongoing innovation across the PBM landscape keeps clients ahead

Managing client and member costs, boosting member adherence and engagement, extending clinical care, and offering consultative expertise that **helps clients meet specific goals** are among the ways PBMs offer ongoing improvement.



Cost containment

Helping clients manage – and lower – pharmacy spend

Helping members stay on track

Improving adherence through better member engagement and access to affordable medications

Managing health conditions

High-touch support for members with chronic conditions to help improve adherence and health outcomes, leading to long-term health care savings

Plan growth

Expertise and strategic support to help clients grow across all lines of business



Controlling costs

Three ways PBMs help payers and patients lower drug and related medical costs



Managing cost and inflation

- Formulary management
- Pharmacy network discounts
- Mail service pharmacy
- Manufacturer discounts and rebates
- Specialty pharmacy
- Specialty channel management



Ensuring the right drug mix


- Generic substitution
- Formularies and therapeutic interchange
- Step therapy
- Copay tiers
- Consumer education
- Specialty pharmacy
- Over the counter



Optimizing adherence

- Fraud, waste and abuse
- Refill too soon
- Quantity limits
- Prior authorization
- Patient adherence
- Specialty pharmacy care management programs

Following the financial flow to understand PBM economics



Near-term specialty pipeline highlights

2024

Potential Patients



lebrikizumab
Atopic dermatitis

4.5M



donanemab
Alzheimer's disease

~4M



sotatercept
Pulmonary hypertension

45K

Anticipated biosimilar launches in immunology class

2024

2025

2029

Actemra (3)
(tocilizumab)

Stelara (6)
(ustekinumab)

Enbrel (2)
(etanercept)

Tysabri (1)
(natalizumab)

Soliris (1)
(eculizumab)

2024-2026
anticipated robust
pipeline

339 new specialty drugs

257 supplemental specialty
indications


28 gene therapy products

45 biosimilar approvals and

37 launches

Balancing cost and coverage for GLP-1s will remain a priority

GLP-1 pharmacy sales forecast \$ in millions



~70%

of current employer client lives have coverage of weight loss medications*

80%

of those clients are using UM controls to provide coverage for appropriate utilization only

300+

clients, representing 6.5M covered lives, enrolled in one or more metabolic health offerings**

UM (Utilization Management).

*Based on BOB employer commercial lives. **Includes Total Diabetes Care, De-prescribing and Weight Management pilot.

Evaluate Pharma, accessed February 20, 2024.

Illustrative example

Applying POS rebates can help reduce high member OOP costs



Rx cost
\$100

Rebate
\$20

Coinsurance
20%

	HDHP without POS rebates			HDHP with POS rebates		
	Fill 1: During deductible	Fill 2: After deductible	Total cost for two fills	Fill 1: During deductible	Fill 2: After deductible	Total cost for two fills
Member	(\$100)	(\$20)	(\$120)	(\$80)	(\$16)	(\$96)
Client	\$20	(\$60)	(\$40)	\$0	(\$64)	(\$64)

POS (Point of service).

A simple equation means more visibility into drug cost economics and pricing

TrueCost net cost guarantee

$$\text{Drug cost} - \text{Rebate} + \text{Dispensing fee} + \text{Admin fee}$$

A disclosed drug mark-up may be applicable on a client-by-client basis, to ensure appropriate pharmacy network reimbursement based on client's pharmacy utilization

©2024 CVS Health and/or one of its affiliates. Confidential and proprietary.

Program savings summary

April 2023-March 2024 Experience Period

Clinical Solution	Intervention Summary	Total Count	Total Gross Savings	Total Net Savings	Total Member Savings
Dose Optimization	Optimized Claims	571	\$23,945		
Drug Savings Review	Drug Savings Review Edits	756		\$549,052	
Pharmacy Advisor Support Gaps in Care Outcomes*	Members With Gap Interventions Eligible For Resolution	56	\$3,894		
	Members with Resolved Gaps	11			
Prior Authorization	Episodes Resulting in PA Approval	1,180			
	Episodes Resulting in PA Denial + Alternative Fill	3			
	Episodes Resulting in PA Denial	219			
	Episodes Resulting in PA Admin Denial	64	\$831,353	\$733,729	
	Episodes Resulting in No PA Requested + Alternative Fill	194			
	Episodes Resulting in No PA Requested	1,784			
Quantity Limits	Episodes Resulting in Full Quantity Filled	111			
	Episodes Resulting in Reduced Quantity Filled	571	\$226,123	\$179,960	
	Episodes Resulting in Target Drug Not Filled	481			
	Episodes Resulting in Full Quantity Filled with Delay	401			
Safety and Monitoring Solutions	Members Targeted	48	\$5,075	\$3,813	
	Case Referrals	2			

* Savings represent Total Healthcare Savings



Program savings summary

April 2023-March 2024 Experience Period

Clinical Solution	Intervention Summary	Total Count	Total Gross Savings	Total Net Savings	Total Member Savings
Specialty Guideline Management	Episodes Resulting in PA Approval	661	\$2,459,569	\$2,395,573	
	Episodes Resulting in PA Denial	135			
	Episodes Resulting in PA Admin Denial	78			
	Episodes Resulting in No PA Requested	74			
Specialty Quantity Limits	Episodes Resulting in Full Quantity Filled	4	\$1,582,062	\$1,538,747	
	Episodes Resulting in Reduced Quantity Filled	33			
	Episodes Resulting in Target Drug Not Filled	2			
	Episodes Resulting in PA Approval	287			
Episodes Resulting in PA Denial + Alternative Fill	42				
Episodes Resulting in PA Denial	365				
Episodes Resulting in PA Admin Denial	68				
Episodes Resulting in No PA Requested + Alternative Fill	11				
Episodes Resulting in No PA Requested	8				
Step with PA					


Key insights and drivers of trend with rebate impact

Key metrics	CEBT	% Change from Prior	Peer
Average Eligible Members	34,870	7.1%	
Total Rx	240,329	7.1%	
Gross Cost Before Rebates	\$55,891,145	14.5%	
Rebates**	\$17,683,238	47.1%	
Specialty Gross Cost	\$30,742,110	16.1%	
Specialty as % of Total Gross Cost	55.0%	1.4%	46.9%
Generic Dispensing Rate	85.4%	1.3%	84.6%

Your trend drivers	Total	Specialty
Price Inflation	1.0%	4.9%
Utilization	2.7%	6.1%
Drug Mix	3.1%	-2.6%


Your top contributors to trend	Contribution to Gross Trend		
	Gross Cost	CEBT	Peer
Overall Class			
Dermatologicals	\$9,437,650	5.9%	2.7%
Antidiabetics	\$8,390,247	1.9%	2.7%
Psychotherapeutic And Neurological Agents - Misc.	\$2,708,921	0.9%	-0.1%
Specialty			
Psoriasis	\$3,295,753	1.9%	1.0%
Crohns Disease	\$3,325,990	1.8%	0.7%
Atopic Dermatitis	\$1,493,811	1.4%	0.8%

Gross Trend with Rebates




Utilization by Channel

- CVS Specialty
- Mail
- Maintenance Choice
- Retail/Other Acute
- Retail/Other Maintenance



Your Gross Cost PMPM



Peer:Government

** Rebates represent client share of invoiced rebates (less: point of sale rebates) as of report run date of 06-18-2024 and may not reconcile with rebate guarantees or rebates paid to date.

Rebates included for this time period: 2023Q3 - 2024Q1. Prior period rebates include the same number of quarters as current period.

©2024 CVS Health and/or one of its affiliates: Confidential & Proprietary

Your top 25 specialty drugs


By gross cost

BOB Rank [†]	Prior Rank	Current Rank	Drug Name	Specialty Class	Total Gross Cost	% of Specialty Gross Cost	Total Utilizers	Total Rx's	Gross Cost Per Rx	Gross Cost Per Days' Supply
1	1	1	Humira	Rheumatoid Arthritis	\$2,172,552	7.07%	40	275	\$7,900.19	\$291.54
3	2	2	Stelara	Crohns Disease	\$2,170,826	7.06%	15	83	\$26,154.53	\$539.20
2	8	3	Skyrizi	Psoriasis	\$1,543,950	5.02%	25	77	\$20,051.30	\$277.09
238	3	4	Kovaltry	Hemophilia	\$1,494,221	4.86%	2	42	\$35,576.69	\$1,509.31
4	5	5	Dupixent	Atopic Dermatitis	\$1,487,359	4.84%	53	349	\$4,261.77	\$148.83
7	7	6	Enbrel	Rheumatoid Arthritis	\$1,235,131	4.02%	25	157	\$7,867.08	\$252.07
10	9	7	Taltz	Psoriasis	\$857,372	2.79%	17	112	\$7,655.11	\$268.60
5	4	8	Humira	Crohns Disease	\$805,460	2.62%	13	97	\$8,303.71	\$284.21
21	24	9	Kesimpta	Multiple Sclerosis	\$651,949	2.12%	11	74	\$8,810.12	\$297.15
18	10	10	Verzenio	Oncology	\$618,625	2.01%	5	41	\$15,088.42	\$538.87
19	16	11	Cosentyx	Psoriatic Arthritis	\$563,418	1.83%	9	68	\$8,285.56	\$295.91
34	21	12	Humira	Inflammatory Bowel Disease	\$545,747	1.78%	8	40	\$13,643.69	\$487.27
25	12	13	Xolair	Asthma	\$535,397	1.74%	27	178	\$3,007.85	\$107.12
20	19	14	Rinvoq	Rheumatoid Arthritis	\$524,728	1.71%	10	85	\$6,173.27	\$205.78
40	35	15	Dupixent	Asthma	\$458,373	1.49%	14	116	\$3,951.49	\$133.64
74	15	16	Enbrel	Ankylosing Spondylitis	\$441,971	1.44%	7	62	\$7,128.56	\$254.59
77	40	17	Opsumit	Pulmonary Arterial Hypertension	\$425,843	1.39%	3	34	\$12,524.79	\$417.49
32	11	18	Xeljanz	Rheumatoid Arthritis	\$401,349	1.31%	8	71	\$5,652.81	\$183.26
33	23	19	Orencia	Rheumatoid Arthritis	\$398,690	1.30%	13	71	\$5,615.35	\$189.85
90	18	20	Rebif	Multiple Sclerosis	\$393,267	1.28%	5	39	\$10,083.76	\$360.13
12	26	21	Humira	Psoriatic Arthritis	\$372,824	1.21%	9	56	\$6,657.58	\$237.77
89	0	22	Mavenclad	Multiple Sclerosis	\$367,891	1.20%	3	5	\$73,578.14	\$383.62
26	58	23	Lenalidomide	Oncology	\$322,483	1.05%	4	24	\$13,436.78	\$500.75
15	17	24	Otezla	Psoriasis	\$293,737	0.96%	12	61	\$4,815.37	\$160.69
76	28	25	Takhzyro	Hereditary Angioedema	\$293,458	0.95%	1	11	\$26,678.01	\$952.79
Total Top Gross Specialty Drugs									\$19,376,621	
Total Top Gross Specialty Drugs/Overall Biotech Specialty Drugs									63.0%	

[†]Employer information is based on the most recent year ending Mar 31, 2024.

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Demonstrating overall value of GLP-1 management



* Net cost prior to managed program savings, AWP discounts, and rebate impact.


**Any UM outcomes savings presented for Prior Authorization (including GLP-1 Smart Edit), Step Therapy, and/or Quantity Limits is for the period Jul-2023 through Apr-2024.

† Rebates represent client share of invoiced rebates as of report run date of 06-18-2024 and may not reconcile with rebate guarantees or rebates paid to date. Rebates included for this time period: 2023Q3 - 2024Q1.

5694-D smart edit management of client GLP-1 spend

Annualized antidiabetic GLP-1 key metrics

Total prescriptions	Total gross cost	Smart-edit savings	Smart-edit savings (%)
5,794	\$7,410,341	\$2,243,600	30%



57%
of members meet smart edit logic

33%
of members did not fill target GLP-1

The smart edit has saved

\$2,243,600

by ensuring proper use of GLP-1 drugs

Source: CVS pharmacy EDW paid claims and PA episode summary data. Claims that hit for Antidiabetic GLP-1/GIP-GLP-1 Drugs with Smart Logic PA within GPI class 2717 identified using PGP CV55694.

[1] Savings annualized and adjusted for client prior GLP-1 specific utilization.

[2] Impact of rebates is NOT included in savings calculation.

[3] Savings and final member fill outcomes are based on current data available at the time the report was run. These metrics could vary if there is additional activity after the data was last refreshed, especially for episodes with less than a 90 day run-out.

Digital solutions help improve clinical outcomes, reduce medication waste and lower health care costs

Key metrics

594 CVS Specialty Utilizers

65 Average Attempted Communications per Utilizer*

24 Average Successful Communications per Utilizer*

577 (97.1% of CVS Specialty Utilizers) Opt-in Digital

465 (80.6% of Opt-In Messaging Utilizers) Filled Online

Digital Breakdown Campaign type

Clinical Messages	1,481	Operational Messages	11,122
Side Effects	521	Order Management	11,109
Adherence	430	Insurance and Billing	13
Condition Management	235		
Symptom and Condition Monitoring	206		
Adherence Monitoring	76		
Safety	8		
Adherence Management	5		

Top 5 drug classes

Specialty Class	Population		Messaging Method		
	CVS Specialty Utilizers	Opt-in Digital Messaging	Text	Email	Both
Rheumatoid Arthritis	106	96.2%	1,497	1,481	175
Crohns Disease	36	97.2%	300	308	9
Psoriasis	66	97.0%	463	454	116
Oncology	36	97.2%	243	218	91
Multiple Sclerosis	38	100.0%	520	468	76

*Average Communications per member are across all communication channels (digital and telephonic)

©2024 CVS Health and/or one of its affiliates: Confidential & Proprietary

Your adherence metrics

Helping patients with **3+** chronic conditions become adherent can increase savings **7 fold**.

% optimal ¹ adherence by most common conditions	CEBT Current Period	CEBT Prior Period	Age Adjusted** Peer*	Age-Adjusted** Employer
Diabetes Total number of adherent utilizers 998	65.1%	72.2%	62.4%	63.5%
Hypertension Total number of adherent utilizers 2,976	74.1%	75.2%	74.4%	73.7%
Hyperlipidemia Total number of adherent utilizers 1,798	76.3%	78.4%	75.1%	74.9%
Heart Failure Total number of adherent utilizers 397	58.3%	53.3%	55.9%	56.2%
Coronary Artery Disease Total number of adherent utilizers 60	64.5%	70.8%	67.6%	68.1%

¹ Optimal: ≥ 80% MPR


*Peer: Government

**Age-adjusted benchmarks represent the optimal adherence % of the book of business segment and peer based on the same age demographics as the client.

©2024 CVS Health and/or one of its affiliates: Confidential & Proprietary

Managing chronic conditions: your adherence measures

Percent optimal¹ adherence by chronic condition



¹ Optimal: ≥ 80% MPR

*Peer: Government


**Age-adjusted benchmarks represent the optimal adherence % of the book of business segment and peer based on the same age demographics as the client.

Membership change affecting cost


Member metrics

	Members that Left The Plan	Members Remaining Eligible in The Plan		Members New to The Plan	
		Jul-May 23	% Change		Jul-May 24
Distinct Eligible Members	6,953	31,645	0.0%	31,645	9,632
Average Eligible Members	3,667	29,078	0.1%	29,110	5,942
Average Member Age	36	35	2.9%	36	32
Percent Utilizing Members	30.7%	29.2%	3.5%	30.2%	24.6%
Gross Cost Per Member Per Month (PMPM)	\$151.51	\$133.52	16.6%	\$155.67	\$92.28
Net Cost Per Member Per Month (PMPM)	\$141.57	\$123.80	17.4%	\$145.40	\$84.53
Days' Supply Per Member Per Month (PMPM)	27.60	25.86	8.5%	28.07	20.34
Rx PMPM	0.67	0.62	4.6%	0.64	0.52
Gross Cost Per Utilizer Per Month (PUMPM)	\$493.86	\$457.91	12.7%	\$515.84	\$374.53
Net Cost Per Utilizer Per Month (PUMPM)	\$461.44	\$424.56	13.5%	\$481.79	\$343.08
Days' Supply Per Utilizer Per Month (PUMPM)	90	89	4.9%	93	83
Rx PUPM	2.20	2.11	1.1%	2.14	2.10


Jul 2022-May 2023 Cost Comparison




Jul 2023-May 2024 Cost Comparison



Jul 2022-May 2023 Utilization Comparison



Jul 2023-May 2024 Utilization Comparison



Brand drugs with upcoming generic launches

Generic outlook

Brand drugs with Jun 2024 - May 2025 generic launches*

Rank	Drug Name	Jul-May 24 Utilizers	Jul-May 24 Total Rxs	Jul-May 24 Net Cost	Jul-May 24 Member Cost	Jul-May 24 Gross Cost
1	Xarelto	175	574	\$545,551	\$46,564	\$592,115
2	Sprycel	2	13	\$144,290	\$520	\$144,810
3	Victoza	18	83	\$95,749	\$4,840	\$100,589
4	Oxtellar Xr	5	30	\$57,106	\$5,058	\$62,164
5	Brilinta	8	25	\$16,727	\$880	\$17,607
6	All Other	0	0	\$0	\$0	\$0
Total		208	725	\$859,423	\$57,862	\$917,284

Brand drugs with Jun 2025 - May 2026 generic launches*

Rank	Drug Name	Jul-May 24 Utilizers	Jul-May 24 Total Rxs	Jul-May 24 Net Cost	Jul-May 24 Member Cost	Jul-May 24 Gross Cost
1	Januvia	69	234	\$234,992	\$16,399	\$251,392
2	Ofev	1	11	\$143,027	\$400	\$143,427
3	Pomalyst	1	5	\$117,321	\$300	\$117,621
4	Janumet Xr	6	20	\$18,801	\$1,680	\$20,481
5	Janumet	4	12	\$16,939	\$1,440	\$18,379
6	All Other	17	66	\$72,746	\$5,798	\$78,544
Total		98	348	\$603,826	\$26,018	\$629,844

*Metrics represent current reporting period utilization and costs of brand drugs, which have anticipated upcoming generic launches.

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Glossary

Glossary of terms

Acute Medication

A prescription drug typically taken for a short period of time, usually a 30-day supply filled at a retail pharmacy.

Adherence—MPR

Medication Possession Ratio (MPR) is the ratio of actual day's supply dispensed to the potential days of use from an initial fill date until the end of the reporting period. Disease state MPR is a weighted average of specific therapeutic class MPR.

Adherence—Optimal

Individuals with Medication Possession Ratio (MPR) or Proportion Days Covered (PDC) of 80% or above during the reporting period.

Adherence—PDC

Proportion Days Covered (PDC) is an alternative way to measure adherence and is used by the Center for Medicare and Medicaid (CMS). PDC is calculated based on fill dates and days supply, but it looks at the number of days between the first fill during the measurement period and the end of the measurement period. Used for Medicare and Exchange clients.

Age-Adjusted Peer

The age-adjusted peer benchmark provides Book of Business projected spend and utilization if the peer had the same age demographics as the client. The age-adjusted benchmark helps to define how age can be a contributing factor that drives a client's overall spend.

Average Wholesale Price (AWP)

Average wholesale price for a prescription drug from the most current pricing information provided by First DataBank, Medi-Span Prescription Pricing Guide (with supplements) or any other nationally available reporting service of pharmaceutical data.

Book of Business (BOB)

This is published data that demonstrates at company level how the various major product lines of the company are performing on different parameters such as adherence and persistency.

Dual Therapy

Patients that are receiving oral as well as injectable drugs for this therapy.

Exclusive Specialty

Pharmacy Network

This program consolidates access to specialty medications solely through CVS Caremark Specialty Pharmacy.

FDA

U.S. Food and Drug Administration

Generic Dispensing Rate (GDR)

The percent of all payable prescriptions that were dispensed as generic drugs.

Generic Substitution Rate (GSR)

The rate, or percent, of generic dispensing that occurred whenever generics were available.

Gross Cost

Client total cost plus member cost.

Maintenance Medication

A prescription drug typically taken on a regular basis to treat a chronic condition, usually a 90-day supply filled at mail or retail pharmacy.

Medical Carve Out

Identification of specialty drugs billed/paid under the medical benefit that could be transitioned to the pharmacy benefit to help ensure high quality clinical management, to decrease costs and increase data transparency.

MinuteClinic®

These are retail-based clinics staffing nurse practitioners and physician assistants treating a limited number of common ailments and offering routine vaccinations. MinuteClinic offers a convenient and cost-friendly option for treatment of certain minor illnesses.

Miscellaneous Drugs

Items classified as "Miscellaneous" are: Products that CVS Caremark dispenses as ancillary medications used for the administration of medication; products dispensed to a utilizing member, per their request, because of the convenience of getting drugs from one site; a single drug in a class/category and/or for a therapy that fits in with other therapies the utilizing member is receiving for a condition.

Glossary of terms (continued)

MSB/SSB

Multi Source Brand/Single Source Brand

Net Cost

Client total amount paid

Non-CVS/specialty

All other pharmacies (traditional, retail or other specialty) other than CVS Caremark Specialty Pharmacies.

Normalized AWP

The CVS Caremark RxInsights® Report normalizes the AWP amount. Given AWP is a calculated field, it relies on the quality of both the quantity dispensed and the AWP price. There are instances where the quantity dispensed does not match with the unit cost which may potentially lead to incorrect amounts. This frequently occurs with compound claims, creams, powders, injectables, etc.

Onboarded

Contacted/engaged by a Care Team (either telephonically or with a "Getting Started" direct mail kit

Over-the-Counter (OTC)

Over-the-counter

PEPM/PEPY

Per Employee Per Month/Per Employee Per Year

PMPM/PMPY

Per Member Per Month/Per Member Per Year

Prevalence

Used to measure the proportion of population that has a specific condition at some time during the reporting period.

PUMPM/PUMPY

Per Utilizing Member Per Month/Per Utilizing Member Per Year

Site of Care Alignment

Analysis of combined medication cost and administration cost to identify circumstances where a lower total costs could potentially be achieved by guiding the member to an alternative site of care or distribution channel

Specialty

Used to treat specific, low-incidence chronic and/or genetic conditions. These products are typically very expensive and may require member-specific dosing, medical devices to administer the medication, and/or special handling and delivery.

Specialty Connect

The integration of our retail and specialty mail pharmacy capabilities. It expands access and convenience to 7,500 CVS Pharmacy locations. Patients can drop off or pick up their specialty prescriptions at a CVS Pharmacy, but the dispensing, drug utilization review and clinical management occurs at our specialty pharmacy.

Specialty Preferred Drug Strategies

Preferred drug list, step therapy and closed formulary strategies encourage utilization of clinically appropriate and lowest net cost medications within select therapeutic categories. These programs positively influence member and prescriber behavior to help reduce cost without compromising quality of care.

Specialty Guideline Management (SGM)

A program that helps ensure appropriate utilization for specialty medications based on evidence-based medicine guidelines and consensus statements. Utilizing member progress is continually assessed to determine whether appropriate therapeutic results are achieved. Standard criteria is available for most specialty drug classes with the ability to implement client-specific criteria.

Trend Components

Provides a breakdown of the independent drivers of gross/net trend. These components have a multiplicative, not additive, relationship with respect to non-biotech gross/net trend. Components of trend include price (average cost per unit), utilization (days' supply PMPM) and product mix (includes new products, changes to the blend of brand and generic drugs, and intensity).

Top therapeutic class description: drug classes, conditions and drug examples

ADHD/Antinarclepsy/Antiobesity Agents

ADHD, Narcolepsy, Obesity
Amphetamine/dextroamphetamine, Focalin XR, Intuniv, Vyvanse, Modafanil, Nuvigil, phentermine, Belviq, Qsymia

Analgesic Anti-inflammatory

Pain and Inflammation, Rheumatoid Arthritis
Ibuprofen, Meloxicam, Naproxen, Diclofenac, Nabumetone, Celebrex, Naprelan, Leflunomide, Enbrel, Humira, Xeljanz

Analgesic Opioid

Pain
Hydrocodone-Acetaminophen, Tramadol, Oxycodone, Oxycodone-Acetaminophen, Fentanyl, Morphine, Nucynta, Suboxone, Subsys

Antiasthmatic and Bronchodilator Agents

Asthma, COPD
Montelukast, Albuterol, Levalbuterol, Budesonide, Advair, Spiriva, Symbicort, Combivent, Dulera, Xolair

Anticonvulsant

Epilepsy, Nerve Pain
Gabapentin, Topiramate, Lamotrigine, Levetiracetam, Divalproex, Oxcarbazepine, Clonazepam, Lyrica, Onfi

Antidepressant

Depression, Anxiety Disorders
Escitalopram, Sertraline, Fluoxetine, Paroxetine, Venlafaxine, Trazodone, Cymbalta, Pristiq, Viibryd

Antidiabetic

Diabetes
Metformin, Glimepiride, Glipizide, Glyburide, Pioglitazone, Lantus, Novolog, Victoza, Byetta, Januvia, Tradjenta

Antihyperlipidemic

High Cholesterol
Atorvastatin, Simvastatin, Livalo, Crestor, Advicor, Simcor, Vytorin, Zetia, Welchol, Niaspan, Lovaza, Vascepa

Antihypertensive

High Blood Pressure
Lisinopril/HCT, Losartan/HCT, Olmesartan/HCT, Valsartan/HCT, Amlodipine-Benazepril, Enalapril, Ramipril, Exforge, Azor, Tekturna, Tarka

Antipsychotic

Bipolar Disorder, Schizophrenia
Olanzapine, Quetiapine, Risperidone, Ziprasidone, Abilify, Geodon, Latuda, Lithium, Haloperidol, Clozapine

Antivirals

HIV/AIDS, Hepatitis C, Herpes, Influenza
Lamivudine, Atripla, Truvada, Isentress, Complera, Stribild, Incivek, Victrelis, Pegasys, Valacyclovir, Tamiflu

Dermatologicals

Acne, Psoriasis, Various Skin Conditions
Adapalene, Triamcinolone acetate, Clindamycin phosphate, Lidoderm, Aldara, Oracea, Epiduo, Stelara

Endocrine and Metabolic

Osteoporosis, Growth Hormone, Infertility
Alendronate, Ibandronate, Actonel, Evista, Forteo, Norditropin, Clomiphene, Follistim, Sensipar, Samsca

Hematologicals

Prevention of Blood Clots, Prevention of Heart Attacks and Stroke, Hemophilia
Clopidogrel, Cilostazol, Dipyridamole, Ticlopidine, Aggrenox, Effient, Brilinta, Advate, Humate-P

Oncology Agents

Breast Cancer, Colorectal Cancer
Gleevec, Xeloda, Temodar, Sprycel, Tarceva, Sutent, Afinitor, Rituxan, Xalkori, Jakafi, Votrient, Inlyta

Psychotherapeutic and Neurological Agents

Alzheimer's Disease, Multiple Sclerosis, Smoking Cessation
Donepezil, Rivastigmine, Exelon patch, Namenda, Horizant, Chantix, Copaxone, Avonex, Gilenya, Aubagio

Ulcer Drugs

Acid Reflux, Ulcers, Heartburn
Omeprazole, Lansoprazole, Pantoprazole, Ranitidine, Famotidine, Cimetidine, Aciphex, Nexium, Dexilant

This is not an all inclusive list.

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Specialty drug classes drug class ID, description and example

AAT (Alpha-1 Antitrypsin Deficiency)

Aralast, Glassia, Prolastin, Zemara

ACROMEGALY (Acromegaly)

Octreotide, Octreotide Acetate, Sandostatin, Signifor Lar, Somatuline, Somavert Depot, Somavert

ALCOHOLISM (Alcohol Dependency)

Probuphine Implant Kit, Vivitrol

ALLERGN (Allergen Immunotherapy)

Oralair

ANEMIA (Anemia)

Aranesp, Epogen, Mircera, Omontys, Procrit, Cinqair, Nucala

ASTHMA (Asthma)

Xolair

BOTULINUMS (Botulinums Toxins)

Botox, Dysport, Myobloc, Xeomin

CAPS (Cryopyrin Associated Periodic Syndromes)

Arcalyst, Ilaris

CARDIAC (Cardiac Disorders)

Dofetilide, Tikosyn

CF (Cystic Fibrosis)

Bethkis, Cayston, Kalydeco, Kitabis Pak, Orkambi, Pulmozyme, Tobi, Tobi Podhaler, Tobramycin

COAGUL (Coagulation Disorders)

Ceprotin

CONTRACEPT (Contraceptives)

Implanon, Klyeena, Liletta, Mirena, Nexplanon, Skyla

CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)

Dupixent

CUSHING'S SYNDROME (Cushing's Syndrome)

Korlym, Signifor

DUPUYTREN (Dupuytren's Contracture)

Xiaflex

ELECTROLYT (Electrolyte Disorders)

Keveyis, Samsca, Veltassa

GI OTHER (Gastrointestinal Disorders-Other)

Cholbam, Gattex, Ocaliva, Solesta

GOUT (Gout)

Krystexxa

HAE (Hereditary Angioedema)

Cinryze, Berinert, Firazyr, Kalbitor

HEMATO (Hematopoietics)

Mozobil, Neumega, Prokine

HEMO (Hemophilia)

Advate, Adynovate, Afstyla, Alphanate, Aphanine, Alprolix, Autoplex T, Bebulin, BeneFIX, Bioclote, Coagadex, Corifact, Elocate, Factor VIII, Feiba, Genarc, Helixate, Hemofil-M, HT Factor, Humate-P, Idelvion, Ixinity, Koate, Kogenate, Kogenate FS, Konyne 80, Kovaltry, Melate, Monarc-M, Monoclate, MonoNine, NovoEight, NovoSeven, Nuwiq, Profi OSD, Profilate, Profilnine, Proplex T, Recombinate, Refacto, RiaSTAP, Rixubis, Stimate, Tretten, Vonvendi, Wilate, Xyntha

HEPB (Hepatitis B)

Adefovir Dipivoxil, Baraclude, Entecavir, Epivir HBV, Hepsera, Lamivudine, Tyzeka, Vemlidy

HEPC (Hepatitis C)

Corpegus, Daklinza, Epclusa, Harvoni, Incivek, Infergen, Moderiba, Olysio, Peg-Intron, Pegasys, Rebetol, Ribapak, Ribasphere, Ribavirin, Sovaldi, Technivie, Victrelis, Viekira, Zepatier

HGH (Growth Hormone and Related Disorders)

Genotropin, Humatrope, Increlex, Norditropin, Nutropin, Omnitrope, Protropin, Saizen, Serostim, Tev-Tropin, Zormacton, Zorbtive

HIV (Human Immunodeficiency Virus)

Injectable: Egrifta, Fuseon

Oral: Agenerase, Aptivus, Atripla, Combivir, Complera, Crixivan, Didanosine (Videx), Edurant, Epivir, Epzicom, Intelence, Kaletra, Lexiva, Norvir, Prezista, Rescriptor, Reyataz, Selzentry, Stavudine (Zerit), Stribild, Sustiva, Trizivir, Truvada, Videx, Viracept, Viread, Ziagen, Zidovudine (Retrovir)

HORM (Hormonal Therapies)

Aveed, Eligard, Firmagon, Leuprolide Acetate, Lupaneta Pack, Lupron, Lupron Depot, Lupron Depot-PED, Natpara, Repositcort, Supprelin, Supprelin LA, Trelstar Depot, Trelstar LA, Trelstar Mixject, Vantas, Viadur, Zoladex

IBD (Inflammatory Bowel Disease)

Cimzia, Entyvio, Remicade, Stelara

IGIV (Immune Deficiencies and Related Disorders)

Carimune, Cytogam, Flebogamma, GamaSTAN S/D, Gamunex, Gammagard, Gammaked, Gammplex, Hepagam B, Hizentra, HyperHEP B, HyperRHO S/D, Iveegam EN, MICRhoGAM, Nabi-HB, Octagam, Polygam S/D, Privigen, RhoGAM, Rhophylac, WinRho SDF

INFECTIOUS (Infectious Disease)

Actimmune, Alferon N

INFERTIL (Infertility)

Bravelle, Cetrotide, Chorionic Gonadotropin (Novarel, Pregnyl), Follistim AQ, Ganirelix Acetate, Gonal-F, Luveris, Menopur, Ovidrel, Repronex

IRON OVERL (Iron Overload)

Deferoxamine, Desferal, Exjade, Ferriprox

ITP (Immune (Idiopathic) Thrombocytopenic Purpura)

Nplate, Promacta

LIPID (Lipid Disorders)

Juxtapid, Kynamro

LIPPCS (Lipid Disorders – PCSK9)

Praulent, Repatha

LIPODYSTROPHY

Myalept

Source: CVS Caremark Data Warehouse & Internal Sources

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

*Drugs are classified according to their primary indication. This is not an all inclusive list.

©2024 CVS Health and/or one of its affiliates: Confidential & Proprietary

Specialty drug classes drug class ID, description and example

LSD (Lysosomal Storage Disorder)

Adagen, Aldurazyme, Cerezyme, Cystagon, Elaprase, Eleyso, Fabrazyme, Myozyme, Naglazyme, VPRIV

MACDEG (Macular Degeneration)

Lucentis, Macugen, Visudyne

MIGRAINE

Zecuity

MISC (Miscellaneous)

Apligraf, Cystadane, Orfadin

MOVEMENT (Movement Disorders)

Apokyn, Xenazine

MS (Multiple Sclerosis)

Ampyra, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Glatopa, Lemtrada, Mitoxantrone, Novantrone, Plegridy, Rebif, Tecfidera, Tysabri, Zinbryta

NEUTROPENIA (Neutropenia)

Leukine, Neulasta, Neupogen

NRAXSPA (Non-Radiographic Axial Spondyloarthritis)

Cimzia Prefilled Syringe, Cosentyx

ONCOL (Oncology)

Injectable: Arzerra, Avastin, Dacogen, Elspar, Erbitux, Erwinaze, Folutyn, Fusilev, Halaven, Herceptin, Intron A, Istodax, Ixempria, Jevtana, mitoxantrone (Novantrone), Oncaspar, Proleukin, Rituxan, Roferan-A, Synribo, Temodar, Thyrogen, Torisel, Treanda, Velstar, Vectibix, Velcade, Xgeva, Zometa and numerous others
Oral/Topical: Afinitor, Bosulif, Cometriq, Eylea, Gleevec, Hycamtin, Iclusig, Jakafi, Nexavar, Revlimid, Sprycel, Stivarga, Sutent, Tarceva, Targretin, Tassigna, Temodar, Thalomid, Tykerb, Votrient, Xalkori, Xeloda, Zelboraf, Zolanza, Zytiga

OSTEOA (Osteoarthritis)

Euflexxa, Hyalgan, Orthovisc, Supartz, Synvisc, Synvisc One

OSTEOP (Osteoporosis)

Forteo Prolia, Reclast

PAH (Pulmonary Arterial Hypertension)

Adcirca, Adempas, Epoprostenol, Flolan, Letairis, Opsumit, Orenitram, Remodulin, Revatio, Sildenafil Citrate, Tracleer, Tyvaso, Uptravi, Veletri, Ventavis

PAIN MANAG (Pain Management)

Prialt

PKU (Phenylketonuria)

Kuvan

PNH (Paroxysmal Nocturnal Hemoglobinuria)

Soliris

PSOR (Psoriasis)

Amevive, Cosentyx, Otezla, Raptiva, Stelara, Taltz

P-T BIRTH (Pre-Term Birth)

Makena

PULMOTH (Pulmonary Disorders – Other)

Esbriet, Ofev

RA (Rheumatoid Arthritis)

Actemra, Enbrel*, Humira*, Inflectra, Kineret, Orencia, Otrexup, Rasuvo, Remicade*, Simponi, Xeljanz

RENAL (Renal Disease)

Sensipar

RETINAL (Retinal Disorders)

Iluvien, Jetrea, Ozurdex, Retisert

RSV (Respiratory Syncytial Virus)

Synagis

SEIZURE (Seizure Disorders)

H.P. Acthar Gel, Sabril

SLE (Systemic Lupus Erythematosus)

Benlysta

SLEEP (Sleep Disorder)

Hetlioz

TRNSPLT (Transplant)

Cellcept, Cyclosporine (Gengraf, Neoral, Sandimmune), Mycophenolate Mofetil (Cellcept), Myfortic, Rapamune, Tacrolimus (Prograf), Zortress

UREA (Urea Cycle Disorders)

Carbaglu

VENOUS INSUFFICIENCY

Varithena

Source: CVS Caremark Data Warehouse & Internal Sources

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

*Drugs are classified according to their primary indication. This is not an all inclusive list

©2024 CVS Health and/or one of its affiliates: Confidential & Proprietary

CVS Health policy statement

All CVS Health presentation materials are confidential and proprietary and may not be copied, distributed, captured, printed or transmitted (in any form) without the written consent/authorization of CVS Pharmacy, Inc.